Efficacy and Safety of AK112 Combined Chemotherapy as Neoadjuvant Treatment for Signet Ring Cell-containing G/GEJ Adenocarcinoma

NCT07091227 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: AK112+oxaliplatin+capecitabine
DRUG: oxaliplatin+capecitabine

Sponsor

Peking Union Medical College Hospital

Collaborators

[object Object]